STOCK TITAN

Lexaria Bioscience Corp. - LEXX STOCK NEWS

Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.

Lexaria Bioscience Corp. (NASDAQ:LEXX) is a pioneering company in the field of drug delivery technology. The company has developed and patented a unique drug delivery platform known as DehydraTECH™, which enhances the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. This technology is notable for significantly improving bio-absorption rates, reducing the onset time of drugs, and masking unpleasant tastes.

DehydraTECH™ has demonstrated remarkable efficacy in enhancing the bio-absorption of cannabinoids and nicotine, increasing their uptake by 5-10 times, and in some cases, by as much as 27 times compared to traditional formulations. This technology also shows potential in improving the delivery of certain drugs through the blood-brain barrier, making it particularly valuable for drugs targeting the central nervous system.

The company operates four key segments: Intellectual Property Licensing, B2B Production, Research and Development, and Corporate. Intellectual Property Licensing is the primary revenue generator for Lexaria, leveraging its robust portfolio of 43 granted patents and numerous pending patents worldwide.

Lexaria's recent endeavors include a series of human and animal studies focused on the application of DehydraTECH™ in enhancing the delivery and efficacy of GLP-1 drugs. These drugs, such as semaglutide and tirzepatide, are primarily used for treating diabetes and promoting weight loss. The company has partnered with the National Research Council of Canada (NRC) to investigate the molecular characteristics and performance of DehydraTECH-processed GLP-1 drugs.

The latest human pilot studies have shown promising results, including higher drug delivery and better blood glucose control with fewer side effects. The company is also exploring the use of DehydraTECH™ for other APIs like cannabidiol (CBD), with applications in treating hypertension and epilepsy.

Recent financial activities include a warrant exercise agreement, raising approximately $4.7 million, which bolsters Lexaria's operational runway into 2025. This financial stability allows the company to pursue its aggressive research and development plans.

Lexaria's innovative approach and continuous research efforts position it as a significant player in the drug delivery technology sector, with the potential to form strategic partnerships with leading pharmaceutical companies.

Rhea-AI Summary

Lexaria Bioscience Corp. has completed dosing in its first human clinical study, HYPER-H21-1, testing the efficacy of its DehydraTECH 2.0 CBD formulation for hypertension treatment. The study involved 24 participants aged 45 to 65, all of whom tolerated the treatment well with no serious adverse effects. Preliminary results are expected by July or August 2021, ahead of the previous Q3 timeline. The company is set to commence the second study, HYPER-H21-2, shortly, involving 16 participants and aiming for swift data analysis and reporting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
-
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced that its DehydraTECH technology effectively inhibited the COVID-19 SARS-CoV-2 virus in an in vitro study using remdesivir and ebastine. The study's preliminary results confirmed the antiviral efficacy of these compounds, paving the way for future in vivo testing. The global antiviral market is projected to exceed USD $44 billion by 2026. Lexaria aims to enhance the oral delivery of these drugs, addressing key challenges in their bioavailability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.17%
Tags
covid-19
-
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) announced remarkable results from its latest DehydraTECH 2.0 cannabidiol (CBD) formulation, achieving a 2,708% improvement in CBD absorption compared to the standard MCT control. This formulation outperformed previous versions, increasing efficacy by 174% over the original DehydraTECH 2.0. The ongoing HYPER-H21-1 human clinical hypertension study is expected to further validate these advancements. Lexaria's research, focused on enhancing drug delivery, positions it favorably in the burgeoning CBD market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
none
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has announced its first patent grant in India, expanding its intellectual property portfolio to a total of 19 patents worldwide. This new patent, titled Stable ready-to-drink beverage compositions comprising lipophilic active agents, is valid for 20 years from December 1, 2016. The patent enhances Lexaria's existing protections in the EU, U.S., and Australia, allowing innovation in ready-to-drink beverages that include various active ingredients like NSAIDs and cannabinoids. Lexaria's patented technology, DehydraTECH™, improves the bio-absorption of these compounds.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
none
-
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced favorable results from its first animal study and the initiation of its first human clinical study as part of its 2021 Hypertension R&D program. CEO Chris Bunka will present at the Benzinga Global Small Cap Conference on May 13, 2021, at 3:50 p.m. ET. The presentation will cover Lexaria's DehydraTECH™ drug delivery technology and its effectiveness in enhancing the delivery of cannabidiol (CBD) for hypertension and other applications. The event aims to connect small-cap companies with investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
conferences
-
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX, NASDAQ:LEXXW) announced successful results from its 2021 study HYPER-A21-1, showcasing its DehydraTECH 2.0 formulations. These new formulations delivered up to 2,178% more CBD into the bloodstream and 1,737% more into brain tissue compared to a standard MCT oil control. The study involved ten rats receiving a 25 mg/Kg dose of CBD over 120 minutes. CEO Chris Bunka emphasized the substantial absorption efficiency of these formulations, which are anticipated to have applications in both pharmaceutical and consumer product markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.07%
Tags
none
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has launched its human clinical hypertension study HYPER-H21-1, examining the effectiveness of its patented DehydraTECH CBD formulation in controlling blood pressure. The study involves 24 volunteers and aims to complete dosing within weeks, with preliminary results expected by July. Secondary objectives include assessing the absorption rate of CBD and related metabolites. Lexaria has 18 granted patents and anticipates further studies to support DehydraTECH's validity as a hypertension treatment. Final results are scheduled for early September 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.34%
Tags
none
-
Rhea-AI Summary

Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) announces the appointment of Gregory Downey as the new Chief Financial Officer effective April 15, 2021. Downey, previously the Company's Controller, brings over ten years of CFO experience and will be compensated with a CDN$144,000 annual salary, a 10% increase, and stock options. The Company also plans to issue 300,000 share purchase warrants to third-party consultants, exercisable until April 16, 2024, at US$9.00 per share. Lexaria continues to advance its DehydraTECH technology for improved drug delivery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
management
-
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX) announced that its client Amari Corp.'s "Everyday Calm" CBD product was recognized as a Top CBD Product Pick by New Hope Network during the Natural Products Expo 2020. This accolade underscores the effectiveness of Lexaria's DehydraTECH technology, which enhances CBD delivery for improved consumer satisfaction. The DehydraTECH platform demonstrates a potential increase in bio-absorption by up to 10x, essential for the growth of CBD products in retail. Lexaria aims to expand the reach of its technology across multiple product formats.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
none
Rhea-AI Summary

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) announced its largest-ever R&D initiative for 2021, targeting four drug markets with a potential value of $87 billion. The studies will focus on enhancing delivery systems for NSAIDs, THC, nicotine, and sildenafil using the DehydraTECH technology. Key market insights include the NSAID market expected to grow to $24.4 billion by 2027 and the cannabis market projected at $40.6 billion by 2024. These initiatives aim to improve drug absorption and speed, with test articles scheduled for manufacturing and dosing in the coming months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Lexaria Bioscience (LEXX)?

The current stock price of Lexaria Bioscience (LEXX) is $2.21 as of December 24, 2024.

What is the market cap of Lexaria Bioscience (LEXX)?

The market cap of Lexaria Bioscience (LEXX) is approximately 38.6M.

What is Lexaria Bioscience Corp. known for?

Lexaria Bioscience Corp. is renowned for its patented DehydraTECH™ drug delivery technology, which enhances the bio-absorption of active pharmaceutical ingredients.

How does DehydraTECH™ improve drug delivery?

DehydraTECH™ enhances drug delivery by increasing bio-absorption rates, reducing the onset time, and masking unpleasant tastes of active pharmaceutical ingredients.

What are the main business segments of Lexaria?

Lexaria operates four main segments: Intellectual Property Licensing, B2B Production, Research and Development, and Corporate.

What recent achievements has Lexaria accomplished?

Recently, Lexaria has shown promising results in human and animal studies using DehydraTECH™ for GLP-1 drugs and raised approximately $4.7 million through a warrant exercise agreement.

What are some key applications of DehydraTECH™?

Key applications of DehydraTECH™ include enhancing the delivery of cannabinoids, nicotine, and GLP-1 drugs, as well as potential uses in hypertension and epilepsy treatments.

How many patents does Lexaria hold?

Lexaria holds a robust portfolio with 43 granted patents and many patents pending worldwide.

What partnerships has Lexaria recently engaged in?

Lexaria has partnered with the National Research Council of Canada (NRC) to investigate the molecular characteristics of DehydraTECH-processed GLP-1 drugs.

What financial activities has Lexaria recently undertaken?

Lexaria recently entered into a warrant exercise agreement, raising approximately $4.7 million to support its operational and R&D activities into 2025.

How does DehydraTECH™ benefit centrally active compounds?

DehydraTECH™ enhances the delivery of drugs across the blood-brain barrier, which is particularly important for centrally active compounds.

Where can I find more information about Lexaria?

For more information, you can visit Lexaria Bioscience Corp.'s official website at www.lexariabioscience.com.

Lexaria Bioscience Corp.

Nasdaq:LEXX

LEXX Rankings

LEXX Stock Data

38.57M
16.18M
7.03%
6.08%
1.96%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
KELOWNA